Peficitinib - Revision history

Prab: CSV import

2025-03-23T18:59:36Z

CSV import

← Older revision		Revision as of 18:59, 23 March 2025
Line 1:		Line 1:
	{{Short description\|~~An overview~~ of ~~the drug Peficitinib~~}}		{{Short description\|A Janus kinase inhibitor used in the treatment of rheumatoid arthritis}}
	{{Drugbox		{{Drugbox
	\| verifiedfields = changed		\| verifiedfields = changed
	\| verifiedrevid = ~~477002547~~		\| verifiedrevid = 477002123
	\| image = Peficitinib.svg		\| image = Peficitinib.svg
	\| ~~image_size~~ = ~~200px~~		\| image2 =
	\| ~~image_alt~~ = Chemical structure of Peficitinib		\| width = 200
			\| alt =
			\| caption = Chemical structure of Peficitinib
	}}		}}

	'''Peficitinib''' is a [[Janus kinase inhibitor]] (JAK inhibitor) used in the treatment of [[rheumatoid arthritis]]. It is ~~a small molecule~~ that ~~selectively inhibits~~ the activity of Janus ~~kinases~~, which ~~are enzymes involved~~ in the ~~signaling pathways of various cytokines and growth factors~~.		'''Peficitinib''' is a [[Janus kinase inhibitor]] (JAK inhibitor) used in the treatment of [[rheumatoid arthritis]]. It is an orally administered medication that works by inhibiting the activity of Janus kinase enzymes, which play a key role in the inflammatory process associated with rheumatoid arthritis.

	==Mechanism of Action==		==Mechanism of Action==
	Peficitinib ~~works~~ by inhibiting the activity of Janus ~~kinases~~, ~~which~~ are ~~crucial for~~ the signaling of ~~several [[~~cytokines~~]] involved in~~ the ~~inflammatory process~~. By blocking these pathways, peficitinib reduces ~~inflammation and~~ the ~~immune~~ response~~, which are central to~~ the ~~pathophysiology~~ of rheumatoid arthritis.		Peficitinib functions by selectively inhibiting the activity of Janus kinase enzymes, particularly JAK1 and JAK3. These enzymes are involved in the signaling pathways of various cytokines and growth factors that are crucial for the immune response and inflammation. By blocking these pathways, peficitinib reduces the inflammatory response and alleviates the symptoms of rheumatoid arthritis.

	~~==Pharmacokinetics==~~
	Peficitinib is administered orally and is absorbed into the bloodstream, where it exerts its effects on the immune system. The drug undergoes metabolism in the liver and is excreted primarily through the kidneys.

	==Clinical Use==		==Clinical Use==
	Peficitinib is primarily used for the treatment of moderate to severe [[rheumatoid arthritis]] in patients who have had an inadequate response to other disease-modifying antirheumatic drugs (DMARDs). It is ~~often used in combination with other~~ therapies ~~to achieve better control of the disease~~.		Peficitinib is primarily used for the treatment of moderate to severe [[rheumatoid arthritis]] in patients who have had an inadequate response to or are intolerant to other disease-modifying antirheumatic drugs (DMARDs). It is administered orally, providing a convenient option for patients compared to injectable therapies.

	==Side Effects==		==Side Effects==
	Common side effects of peficitinib include ~~[[headache]], [[nausea]], and [[~~upper respiratory tract infections]]. ~~More serious~~ side effects ~~can~~ include ~~increased risk of~~ infections, ~~[[liver enzyme]] abnormalities~~, and ~~[[hematological]] changes~~ such as anemia and neutropenia.		Common side effects of peficitinib include upper respiratory tract infections, headache, and increased liver enzymes. Serious side effects may include infections, gastrointestinal perforations, and hematologic abnormalities such as anemia and neutropenia. Patients on peficitinib require regular monitoring for these potential adverse effects.

	==Development and Approval==		==Development and Approval==
	Peficitinib was developed ~~as part of ongoing research into JAK inhibitors for the treatment of autoimmune diseases. It~~ has been approved for use in several countries ~~and is undergoing further studies~~ to ~~evaluate~~ its efficacy and safety ~~in other conditions~~.		Peficitinib was developed by [[Astellas Pharma]] and has been approved for use in several countries for the treatment of rheumatoid arthritis. Its development involved extensive clinical trials to establish its efficacy and safety profile.

	==Related ~~pages~~==		==Related Pages==
	* [[Rheumatoid arthritis]]		* [[Rheumatoid arthritis]]
	* [[Janus kinase inhibitor]]		* [[Janus kinase inhibitor]]
	* [[~~Cytokine~~]]		* [[Astellas Pharma]]

	[[Category:Janus kinase inhibitors]]		[[Category:Janus kinase inhibitors]]
	[[Category:Antirheumatic ~~agents~~]]		[[Category:Antirheumatic products]]
	~~<gallery>~~		[[Category:Drugs acting on the immune system]]
	~~File~~:~~Peficitinib.svg\|Peficitinib~~
	~~</gallery>~~
	~~<gallery>~~
	~~File:Peficitinib.svg\|Peficitinib~~
	~~</gallery>~~

Prab: CSV import

2025-02-20T01:25:08Z

CSV import

← Older revision		Revision as of 01:25, 20 February 2025
Line 32:		Line 32:
	[[Category:Janus kinase inhibitors]]		[[Category:Janus kinase inhibitors]]
	[[Category:Antirheumatic agents]]		[[Category:Antirheumatic agents]]
			<gallery>
			File:Peficitinib.svg\|Peficitinib
			</gallery>
	<gallery>		<gallery>
	File:Peficitinib.svg\|Peficitinib		File:Peficitinib.svg\|Peficitinib
	</gallery>		</gallery>

Prab: CSV import

2025-02-20T01:08:09Z

CSV import

← Older revision		Revision as of 01:08, 20 February 2025
Line 32:		Line 32:
	[[Category:Janus kinase inhibitors]]		[[Category:Janus kinase inhibitors]]
	[[Category:Antirheumatic agents]]		[[Category:Antirheumatic agents]]
			<gallery>
			File:Peficitinib.svg\|Peficitinib
			</gallery>

Prab: CSV import

2025-02-13T03:40:19Z

CSV import

← Older revision		Revision as of 03:40, 13 February 2025
Line 1:		Line 1:
	~~'''~~Peficitinib~~''' is an oral [[Janus kinase inhibitor]] developed by [[Astellas Pharma]] for the treatment~~ of ~~[[rheumatoid arthritis]]. It is currently approved for use in Japan and is undergoing clinical trials in other countries.~~		{{Short description\|An overview of the drug Peficitinib}}
			{{Drugbox
			\| verifiedfields = changed
			\| verifiedrevid = 477002547
			\| image = Peficitinib.svg
			\| image_size = 200px
			\| image_alt = Chemical structure of Peficitinib
			}}

	~~== Mechanism~~ of ~~Action ==~~		'''Peficitinib''' is a [[Janus kinase inhibitor]] (JAK inhibitor) used in the treatment of [[rheumatoid arthritis]]. It is a small molecule that selectively inhibits the activity of Janus kinases, which are enzymes involved in the signaling pathways of various cytokines and growth factors.

	Peficitinib works by inhibiting the [[Janus ~~kinase (JAK)]] family of enzymes~~, which are ~~involved in~~ the signaling ~~pathways~~ of ~~various~~ [[cytokines]] ~~and [[growth factors]] that are important for [[hematopoiesis]] and immune cell function~~. By ~~inhibiting~~ these ~~enzymes~~, peficitinib ~~can reduce~~ inflammation and ~~other symptoms~~ of rheumatoid arthritis.		==Mechanism of Action==
			Peficitinib works by inhibiting the activity of Janus kinases, which are crucial for the signaling of several [[cytokines]] involved in the inflammatory process. By blocking these pathways, peficitinib reduces inflammation and the immune response, which are central to the pathophysiology of rheumatoid arthritis.

	== ~~Clinical Trials~~ ==		==Pharmacokinetics==
			Peficitinib is administered orally and is absorbed into the bloodstream, where it exerts its effects on the immune system. The drug undergoes metabolism in the liver and is excreted primarily through the kidneys.

	Peficitinib ~~has undergone several~~ [[~~clinical trials~~]] to ~~evaluate its safety and efficacy in treating rheumatoid arthritis~~. ~~In a Phase 3 trial conducted~~ in ~~Japan, peficitinib was found~~ to ~~be effective in reducing~~ the ~~signs and symptoms of rheumatoid arthritis, and had a safety profile consistent with other JAK inhibitors~~.		==Clinical Use==
			Peficitinib is primarily used for the treatment of moderate to severe [[rheumatoid arthritis]] in patients who have had an inadequate response to other disease-modifying antirheumatic drugs (DMARDs). It is often used in combination with other therapies to achieve better control of the disease.

	== Side Effects ==		==Side Effects==
			Common side effects of peficitinib include [[headache]], [[nausea]], and [[upper respiratory tract infections]]. More serious side effects can include increased risk of infections, [[liver enzyme]] abnormalities, and [[hematological]] changes such as anemia and neutropenia.

	~~Common side effects~~ of ~~peficitinib include [[nausea]], [[diarrhea]], and [[upper respiratory tract infection]]~~. ~~Serious side effects can include [[anemia]], [[neutropenia]],~~ and ~~[[thrombocytopenia]]. Patients taking peficitinib should be monitored for these~~ and other ~~potential side effects~~.		==Development and Approval==
			Peficitinib was developed as part of ongoing research into JAK inhibitors for the treatment of autoimmune diseases. It has been approved for use in several countries and is undergoing further studies to evaluate its efficacy and safety in other conditions.
	~~== See Also ==~~

			==Related pages==
			* [[Rheumatoid arthritis]]
	* [[Janus kinase inhibitor]]		* [[Janus kinase inhibitor]]
	* [[~~Rheumatoid arthritis~~]]		* [[Cytokine]]
	* [[Astellas Pharma]]

	~~== References ==~~

	~~<references />~~

	~~[[Category:Drugs]]~~
	~~[[Category:Rheumatoid arthritis]]~~
	[[Category:Janus kinase inhibitors]]		[[Category:Janus kinase inhibitors]]
			[[Category:Antirheumatic agents]]
	~~{{stub}}~~

Prab: CSV import

2024-02-22T04:23:28Z

CSV import

New page

'''Peficitinib''' is an oral [[Janus kinase inhibitor]] developed by [[Astellas Pharma]] for the treatment of [[rheumatoid arthritis]]. It is currently approved for use in Japan and is undergoing clinical trials in other countries.

== Mechanism of Action ==

Peficitinib works by inhibiting the [[Janus kinase (JAK)]] family of enzymes, which are involved in the signaling pathways of various [[cytokines]] and [[growth factors]] that are important for [[hematopoiesis]] and immune cell function. By inhibiting these enzymes, peficitinib can reduce inflammation and other symptoms of rheumatoid arthritis.

== Clinical Trials ==

Peficitinib has undergone several [[clinical trials]] to evaluate its safety and efficacy in treating rheumatoid arthritis. In a Phase 3 trial conducted in Japan, peficitinib was found to be effective in reducing the signs and symptoms of rheumatoid arthritis, and had a safety profile consistent with other JAK inhibitors.

== Side Effects ==

Common side effects of peficitinib include [[nausea]], [[diarrhea]], and [[upper respiratory tract infection]]. Serious side effects can include [[anemia]], [[neutropenia]], and [[thrombocytopenia]]. Patients taking peficitinib should be monitored for these and other potential side effects.

== See Also ==

* [[Janus kinase inhibitor]]
* [[Rheumatoid arthritis]]
* [[Astellas Pharma]]

== References ==

<references />

[[Category:Drugs]]
[[Category:Rheumatoid arthritis]]
[[Category:Janus kinase inhibitors]]

{{stub}}